Icotrokinra vs Pasireotide
Overview
Icotrokinra is primarily a immune support peptide, while Pasireotide is used for hormonal.
This page compares Icotrokinra and Pasireotide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Icotrokinra | Pasireotide | |
|---|---|---|
| Category | Immune Support | Hormonal |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | — | 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) |
| Frequency | — | Twice daily (SC formulation) or every 4 weeks (LAR formulation) |
| Reported benefits | — | Reduction of cortisol hypersecretion in Cushing's disease, normalization of GH and IGF-1 in acromegaly, pituitary tumor volume reduction, improvement of clinical signs of hypercortisolism |
| Reported side effects | — | Hyperglycemia, new-onset or worsening diabetes mellitus, diarrhea, nausea, cholelithiasis, QT interval prolongation, bradycardia, hepatic enzyme elevation, adrenal insufficiency (hypocortisolism) |
Key differences
Primary use. Icotrokinra is categorised under Immune Support, while Pasireotide falls under Hormonal. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Icotrokinra: FDA-approved. Pasireotide: FDA-approved.
Dosing. Typical dosing for Icotrokinra is not catalogued. Pasireotide is typically dosed at 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) (Twice daily (SC formulation) or every 4 weeks (LAR formulation)).
Can you stack them?
Some protocols combine peptides, but stacking Icotrokinra and Pasireotide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Icotrokinra and Pasireotide?
- Icotrokinra is primarily a immune support peptide, while Pasireotide is used for hormonal. Icotrokinra is FDA-approved for one or more indications, whereas Pasireotide is FDA-approved for one or more indications.
- What is Icotrokinra used for?
- Oral macrocyclic peptide. First-in-class IL-23 receptor antagonist. FDA approved March 17, 2026 for plaque psoriasis.
- What is Pasireotide used for?
- Multi-receptor somatostatin analog (Signifor/Signifor LAR) FDA-approved for Cushing's disease and acromegaly.
- Can you take Icotrokinra and Pasireotide together?
- Some users combine peptides within a single protocol, but stacking Icotrokinra and Pasireotide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Icotrokinra or Pasireotide FDA-approved?
- Icotrokinra is FDA-approved for one or more indications. Pasireotide is FDA-approved for one or more indications.
Read the full articles
- Icotrokinra — full monograph: mechanism, research, dosing & references
- Pasireotide — full monograph: mechanism, research, dosing & references